Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Stand Up To Cancer funding totaling more than $6 million to Johns Hopkins investigators was awarded in May 2009. The grants, established by the Entertainment Industry Foundation are funded with proceeds raised during a simultaneous primetime television broadcast on ABC, CBS and NBC television networks and other fundraising initiatives. Two awards to Johns Hopkins-led teams were chosen by a 20-member panel of scientists, physicians, and patient advocates who reviewed more than 200 applications.
EPIGENETICS DREAM TEAM
Leader: Stephen Baylin, M.D., deputy director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Co-Leader: Peter A. Jones, Ph.D., D.Sc., director, University of Southern California, Norris Comprehensive Cancer Center
This $9.12 million, three-year grant will study epigenetic changes that modify the way a cell packages its DNA sequence for regulating gene function. Abnormal DNA packaging silences genes that confer cancer protection in people with lung, breast and colon cancers. The Epigenetics Dream Team will conduct clinical trials and laboratory investigations to test potential treatments to reverse this silencing of genes.
- Epigenetics Dream Team Members
- What is Epigenetics? Read more about a relatively new field of research directed at understanding and manipulating gene alterations that can shut down natural cancer protection.
- Clinical Trials Information
PANCREAS CANCER DREAM TEAM
Leaders: Craig Thompson, M.D., director of Memorial Sloan-Kettering Cancer Center and Daniel Von Hoff, M.D., physician-in-chief and director of the Clinical Translational Research Division at the Translational Genomics Research Institute
Scientists at Johns Hopkins were awarded $3.75 million plus clinical trial funding to test and develop drugs that target faulty enzymes that process glutamine and glucose and fatty acids in some pancreatic cancers. Johns Hopkins investigators also will scan patients' genomes for genes that could benefit from glutamine and glucose-blocking drugs and track drug responses.
Johns Hopkins investigators:
Ralph Hruban, M.D.
Kenneth Kinzler, Ph.D.
Daniel Laheru, M.D.
Martin Pomper, M.D., Ph.D.
Victor Velculescu, M.D., Ph.D.